Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX4 | Q99571 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | PLA2G2A | P14555 | 13/20 | 0.49 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18084007 | 0.93 | P2RX4 (0.54) | P2RX4KMT2ATSHRMAPK1MAPT | |
| SCHEMBL18083982 | 0.92 | P2RX4 (0.47) | P2RX4KMT2ATSHRMAPK1PLA2G2A | |
| SCHEMBL18083995 | 0.90 | P2RX4 (0.47) | P2RX4KMT2ATSHRMAPK1PLA2G2A | |
| SCHEMBL30822886 | 0.88 | P2RX4 (0.45) | P2RX4KMT2APLA2G2AMAPTALDH1A1 | |
| SCHEMBL18083987 | 0.88 | P2RX4 (0.45) | P2RX4KMT2APLA2G2AMAPTALDH1A1 | |
| SCHEMBL17449597 | 0.87 | CYP19A1 (0.55) | P2RX4KMT2AMAPK1MAPTALDH1A1 | |
| SCHEMBL29354558 | 0.87 | CYP19A1 (0.55) | P2RX4KMT2AMAPK1MAPTALDH1A1 | |
| SCHEMBL18083981 | 0.86 | GRIK2 (0.43) | P2RX4KMT2AMAPTALDH1A1POLB | |
| SCHEMBL17965656 | 0.84 | CYP19A1 (0.66) | P2RX4KMT2AMAPK1MAPTALDH1A1 | |
| SCHEMBL19821768 | 0.84 | P2RX4 (0.45) | P2RX4KMT2ATSHRMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10403445-B2 | Synthons for developing organic semiconductors | UNIVERSITÉ DE TOURS (FR) | 2019-09-03 | — | — | US | disclosed |
| US-10403445-B2 | Synthons for developing organic semiconductors | UNIVERSITÉ DE TOURS (FR) | 2019-09-03 | — | — | US | disclosed |
| US-20170213652-A1 | NOVEL SYNTHONS FOR DEVELOPING ORGANIC SEMICONDUCTORS | UNIVERSITÉ DE TOURS (FR) | 2017-07-27 | — | — | US | disclosed |
| US-20170213652-A1 | NOVEL SYNTHONS FOR DEVELOPING ORGANIC SEMICONDUCTORS | UNIVERSITÉ DE TOURS (FR) | 2017-07-27 | — | — | US | disclosed |
| US-20170213652-A1 | NOVEL SYNTHONS FOR DEVELOPING ORGANIC SEMICONDUCTORS | UNIVERSITÉ DE TOURS (FR) | 2017-07-27 | — | — | US | disclosed |
| WO-2016016221-A1 | NOVEL SYNTHONS FOR DEVELOPING ORGANIC SEMICONDUCTORS | UNIVERSITE DE TOURS FRANCOIS-RABELAIS (FR) | 2016-02-04 | — | — | WO | disclosed |
| EP-2966145-A1 | Carbazole based hole transport materials | Dyenamo AB (SE) | 2016-01-13 | — | — | EP | disclosed |
| EP-2966145-A1 | Carbazole based hole transport materials | Dyenamo AB (SE) | 2016-01-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170213652-A1 | NOVEL SYNTHONS FOR DEVELOPING ORGANIC SEMICONDUCTORS | NES, NCL, CDK6 | P2RX4 4383/4885KMT2A 1940/4885TSHR 2309/4885 |
| US-10403445-B2 | Synthons for developing organic semiconductors | NES, NCL, PCNA | P2RX4 4205/4885KMT2A 2020/4885TSHR 1926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.